Trellis selects CMC Biologics to make mAb therapies

By Flora Southey

- Last updated on GMT

iStock/media point inc
iStock/media point inc

Related tags: Cmc biologics, Bacteria, Microbiology

CMC Biologics and Trellis Bioscience are teaming up to make monoclonal antibody (mAb)-based therapies.

Under the terms of the agreement, CMC Biologics, which is owned by Asahi Glass Compnay, will employ its proprietary CHEF1 expression platform and multi-column continuous chromatography (MCC) technology to develop and manufacture two of Trellis’ mAbs.

Trellis CEO Stefan Ryser said the mAb-based therapies aim to treat respiratory syncytial virus (RSV) infections and bacterial infections respectively.

Ryser said the RSV infection-focused therapy “promises to provide superior post-infection treatment over the currently marketed mAb (palivizumab) by uniquely combining antiviral and anti-inflammatory activity.”

The other candidate – TRL1068 – is designed to treat bacterial infections that are drug-resistant due to the formation of bacterial biofilms.

“By disrupting the biofilm, TRL1068 acts to resensitise bacteria to conventional antibiotics, with broad-spectrum activity spanning from medically important gram-positive to gram-negative bacterial species, including MRSA​ [methicillin resistant staphylococcus aureus antibody] and Acinetobacter baumanni,”​ Ryser explained.

Cost reduction

According to Ryser, the use of CMC Biologics’ technologies will reduce costs in the downstream process.

“Through CMC Biologics’ use of MCC technology, where a reduced quantity of costly chromatography resins is required in the downstream process, CMC Biologics is able to provide Trellis a significant reduction in our development and manufacturing costs.” 

Related topics: Downstream Processing

Related news

Show more